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INTRODUCTION
DA-9701, a new herbal drug for the treatment of functional dyspepsia (FD), was developed by Dong-A Pharmaceutical in Korea. The drug received New Drug Application (NDA) approval in May 2011 from the KFDA (Korea Food and Drug Administration). It is formulated as a 50% ethanol extract from Corydalis Tuber and Pharbitidis Semen.
FD is a complex of dyspeptic symptoms including upper abdominal pain, heartburn, bloating, and discomfort (Stanghellini et al., 2003) . These symptoms are thought to originate from the upper abdomen but their structural and organic causes are not known (Halder and Talley, 2007) . The pathophysiology of FD is not simple, and is known to have multiple causes including delayed gastric emptying, impaired gastric accommodation, visceral hypersensitivity, small bowel dysmotility, genetic factors, social stress, and infl ammation (Brun and Kuo, 2010) . Among them, impaired gastric accommodation, visceral hypersensitivity and delayed gastric emptying are known to be the major pathophysiological causes of FD (Brun and Kuo, 2010) . Fig. 1 shows pathophysiology of FD and drug target. Delayed gastric emptying is a traditional therapeutic target of gastroprokinetics (Stanghellini et al., 2004) . Visceral hypersensitivity is a common cause of functional gastrointestinal diseases and there is no established treatment for visceral hypersensitivity (Talley et al., 2012) . However, off-label antidepressants have been frequently prescribed for visceral pain management (Talley et al., 2012) . Impaired gastric accommodation was reported to be related to early satiety and a 181-189 (2013) http://dx.doi.org/10.4062/biomolther.2012.096 piride and so on. However, the need for good effi cacy and safety is still unmet. Besides, Tegaserod was withdrawn from the market due to cardiovascular side effect and D 2 antagonists were known to induce hyperprolactinemia. The effi cacy of these agents is narrowed to prokinetic effect. Recently acotiamide and STW 5 were launched into market. Acotiamide, a muscarinic antagonist was developed as prokinetics but failed to correct delayed gastric emptying in clinical trial while showing symptomatic relief and lack of dose response (Tack and Janssen, 2011a) . Besides, the dose of symptomatic relief and effi cacy for increasing accommodation didn't match (Tack and Janssen, 2011a) . STW 5 (Iberogast ® ) is a phytomedicine consisted of nine herbs. It as a leading phytomedicine has been used for more than 40 years (Rosch et al., 2006) and studied abundantly. Interestingly acotiamide has been known to increase gastric accommodation and STW 5 also has multiple action mechanism including fundus relaxation (Schemann et al., 2006) . Moreover, DA-9701 has been known to increase gastric accommodation in vivo (Kim et al., 2012) beyond prokinetic effect and visceral analgesic effect. These new agents and the effi cacy on fundus relaxation seem to refl ect increasing importance of gastric accommodation in pathophysiology of FD. Multiple action mechanism including fundus relaxation effi cacy may be more suitable for chronic complex disease than single action, which will be verifi ed before long.
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DA-9701: A HERBAL COMBINATION
DA-9701 is formulated with Pharbitidis Semen and Corydalis Tuber. Corydalis Tuber had been used in traditional medicine for the treatment of gastric (Soji et al., 1969) and duodenal ulcers (Kamigauchi and Iwasa, 1994) and dysmenorrhea (Jia et al., 2006) . Extracts from Corydalis Tuber have been used as antispasmodic agents for the gastrointestinal tract and as analgesics (Ding et al., 2007) . Pharbitidis Semen is the seed of Pharbitis nil Choisy of the Convolvulaceae family and has been used as a folk medicine for its analgesic effects on the abdomen (Kumar et al., 2009) .
Compared to non-botanical drugs, extracts of herbal material mixtures require more complicated quality control. Various analyses were performed for quality certifi cation. The tests included identifi cation of herbal material and extracts, loss on drying, inorganic impurities (like heavy metals), microbial limits, and pesticides, and chemical assays. Botanical materials are complex mixtures of numerous chemical constituents. Highperformance liquid chromatography (HPLC) performed for batch-to-batch control revealed corydaline and chlorogenic acid as the major constituents.
THE PHARMACOLOGY OF DA-9701
The in vivo pharmacological study results of DA-9701 were summarized in Table 2 and in vitro receptor affi nities to major receptor related to gastrointestinal function were summarized in Table 3 including comparison with other prokinetics.
Fundus relaxation eff ect
Impaired gastric accommodation is one of major therapeutic targets in FD. There are 2 kinds of responses in proximal gastric relaxation. One is "receptive relaxation" (Cannon and decrease of weight gain. Previously, there have been no treatments termed fundic relaxants (Tack and Janssen, 2011b) .
In Rome II criteria (Drossman, 1999) , FD was defi ned as recurrent upper abdominal pain and discomfort for at least 12 weeks during the preceding 1 year. The Rome II classifi cation divided patients having a wide range of dyspepsia symptoms into 4 groups on the basis of the major symptomatic pattern: refl ux-like, ulcer-like, dysmotility-like, or nonspecifi c FD. The criteria excluded patients with predominant heartburn (refl ux-like pattern) from the dyspepsia spectrum (Suzuki et al., 2006) . In Rome III criteria, the defi nition of FD was less restrictive and had a shorter time frame (3 months of symptoms in the previous 6 months). The symptomatic categorization of Rome II was not reliable because of frequent overlap among irritable bowel syndrome (IBS), gastroesophageal refl ux disease (GERD), postprandial distress syndrome (PDS), and epigastric pain syndrome (EPS) (Suzuki et al., 2006) . Due to this reason, amongst others, the Rome III committee decided to categorize FD into 2 groups for the purpose of therapeutic research and clinical utility: PDS and EPS . Major symptoms of FD include postprandial fullness, early satiety, epigastric pain, and epigastric burning. Nausea, vomiting, and heartburn, which were included under FD symptoms under the Rome II criteria, were moved to other categories.
The prevalence of FD was reported to be about 20% in western countries (Talley et al., 1992; Agreus et al., 1995; Piessevaux et al., 2009) . In Korea the prevalence of FD was reported to be 13.4% on using the Rome II criteria, with the dysmotility type being dominant (Rhie et al., 2007) . On using the Rome III criteria, the prevalence was reported to be 8.1% (EPS, 4.6% and PDS, 6.5%) (Noh et al., 2010) . FD signifi cantly decreases patients' quality of life and increases social cost.
The multiple mechanisms involved in the pathophysiology of FD seem to make it diffi cult for a new FD drug to reach a satisfactory effi cacy level, or even for it to be appropriately evaluated. Further, opinion leaders worldwide have said that an agent that is able to modulate multiple mechanisms will be more promising than an agent highly selective for a single mechanism and that a new drug for FD should target all or many pathophysiological targets . DA-9701 was developed to have multiple action mechanisms by combining herbs, and fi nally, Pharbitidis Semen and Corydalis Tuber were selected. The pharmacology concerning the multiple action mechanisms of DA-9701 and some associated safety issues are reviewed here.
CURRENT STATUS OF DRUG DEVELOPMENT FOR TRE-ATMENT OF FD
Currently, major drugs prescribed for treatment of FD are gastrointestinal prokinetics. After withdrawal of cisapride due to its cardiovascular side effects, several prokinetic agents were developed to have lower safety concerns. There were numerous attempts to develop new agent for treatment of functional dyspepsia and their clinical study results are summarized in Table 1 . Major end point of clinical trial were symptomatic relief and correction of pathophysiological cause such as delayed gastric emptying, impaired gastric accommodation and visceral hypersensitivity. Some of them succeeded in showing effi cacy and launched into the market. They are tegaserod, itopride, mosapride, domperidone, metoclopramide, levosul-www.biomolther.org 
Prokinetics
5-HT 4 receptor agonists
Cisapride Accelerated gastric emptying of patients with functional dyspepsia (Degryse et al., 1993) Enhanced perception of gastric distension and the gastric accommodation to a meal in health (Tack et al., 1998a) Tegaserod Accelerates gastric emptying and gastrointestinal transit in healthy subject (Degen et al., 2001) Enhanced gastric accommodation in health and in FD (Tack et al., 2003b) No signifi cant effect on gastric motor and sensory function in healthy individuals ) Renzapride Enhances gastric emptying in health and in diabetic gastroparesis (Mackie et al., 1991) Mosapride Enhances gastric emptying in health (Kanaizumi et al., 1991) Phase 2 in FD: no benefi t over placebo (Hallerback et al., 2002) 
Itopride
Decreases gastric accommodation in health (Choung et al., 2007) Acceleration of gastric emptying: benefi t shown by a placebo-controlled trial in diabetic patients (Stevens et al., 2008) Phase 2 in FD signifi cant benefi t (Choung et al., 2007) Phase 3 in FD no benefi t over placebo (Banani et al., 2008) Accelerated antral emptying in FD (Dumitrascu et al., 1998) Metoclopramide signifi cantly improved delayed gastric emptying (Hancock et al., 1974 Enhances gastric emptying in diabetic gastroparesis patients (Ejskjaer et al., 2009) 
Fundic relaxants
Nitrates Nitroglycerine Enhances gastric accommodation in health and in FD (Gilja et al., 1997) 
PDE inhibitors
Sildenafi l Enhances gastric accommodation in health and delays gastric emptying in health (Sarnelli et al., 2004 ) SSRI Paroxetine Enhances gastric accommodation in health (Tack et al., 2003a) Relaxes the proximal stomach in health (Boeckxstaens et al., 2006) Phase 2 in FD: no benefi t over placebo (Tack et al., 2009b ) M1/M2 muscarinic receptor blockers
Acotiamide
May enhance accommodation in FD Phase 2a in FD: potential benefi t (Tack et al., 2009a) Phase 3 in FD: over 4 weeks, signifi cantly improved symptom severity and eliminated mealRelated symptoms in patients with FD (Matsueda et al., 2012) Visceral analgesics 5-HT 3 antagonist Alosetron Reduction of visceral hypersensitivity (Delvaux et al., 1998) Benefi t shown by a placebo-controlled trial (Dukes et al., 2000) Opioid k agonist Fedotozine Reduction of visceral hypersensitivity in healthy (Coffi n et al., 1996) Benefi t shown by a placebo-controlled trial (Read et al., 1997 ) NK-1 antagonist Aprepitant No infl uence on gastrointestinal motility in healthy volunteers (Madsen and Fuglsang, 2008 ) NK-3 antagonist Talnetant No effect on rectal compliance or distension-induced rectal sensation in healthy participants (Houghton et al., 2007) http://dx.doi.org/10.4062/biomolther.2012.096 Lieb, 1911) , and the other is "adaptive relaxation" (Jahnberg et al., 1975) , a synonym of accommodation. Receptive relaxation occurs when swallowing foods, and adaptive relaxation initiates with entrance of the chyme to the duodenum and lasts for a period of time. In FD patients, impaired gastric accommodation prevalence was reported up to about 40%, and it was reported that impaired accommodation was related to early satiety and weight decrease (Bisschops and Tack, 2007) . Currently there are limited available animal models for evaluating the fundus relaxing effect. In humans, the barostat method is the gold standard to measure gastric tone and accommodation (Mundt et al., 2002; Tomita et al., 2013) . Most of the well-known studies on fundus relaxation are using barostat in the canine (Azpiroz and Malagelada, 1985; Lei et al., 2005; Yin et al., 2007) , but rat (Graca et al., 2002; Monroe et al., 2004; Romer et al., 2005; Zhao et al., 2005) , ferret (Blackshaw et al., 1987) and feline (Mayrand et al., 1994; Janssen et al., 2004) are also known in vivo models. There are 2 kinds of end points evaluating fundus relaxation in the canine barostat model: accommodation and compliance (Azpiroz and Malagelada, 1985; De Ponti et al., 2003) . The physiological gastric accommodation response enables relaxation of the proximal stomach providing space to receive foods without an increase in gastric pressure (Azpiroz and Malagelada, 1986) . Especially meal-induced gastric accommodation is thought to be the most important motor index that can be studied in this model, since it is impaired in FD patients and it is a physiological test (Tack, 2009) . Gastric compliance, which is tested in the fasting state, measures gastric tone in the resting state, and seems to be related to pain and discomfort perception threshold Kuiken et al., 2005) . Sumatriptan, known as a migraine treatment, was reported to enhance gastric accommodation in both humans and canines. Additionally, the triptan class of drugs was reported to have enhancing effects on gastric accommodation in canine (Moro et al., 2004) . However, currently there is no established fundic relaxant and some agents are in development (Tack and Janssen, 2011b) .
It was evaluated that DA-9701 can relax the proximal stomach in dog. The fundus relaxing effect was fi rst established Active at 3 mg/kg po In vivo Imrovement of delayed gastric emptying induced by stress and inhibition of stress related hormones Rat, stress induced delayed gastric emptying
Active at 3 mg/kg (Jung et al., 2013) In vivo Antinociceptive effect against www.biomolther.org using the gastric compliance model, and it was shown that the pressure volume curve was shifted left and up in the DA-9701 treated group . Also, in the meal-induced gastric accommodation model, DA-9701 increased the intragastric volume more than in the vehicle-treated group, and this lasted for more than the normal accommodation response in dog barostat studies (approximately 1 h) (Kim et al., 2012) . DA-9701 may be effective to treat stress-related disorders because one of its active ingredients (AI), tetrahydroberberine (THB), alleviates impaired gastric compliance in the poststress rat (Lee et al., 2011) , and it prevented stress induced feeding inhibition . The common mechanism between stress-induced feeding inhibition and impaired gastric relaxation is not known. However, it is known that THB relaxes the proximal stomach via 5-HT 1A agonism (Lee et al., 2011) and that DA-9701 signifi cantly inhibits feeding inhibition induced by restraint stress via 5-HT 1A activation in the rat . DA-9701 also has 5-HT 4 and adrenergic α 2 agonistic properties but it is not fully established that activation of these receptors effect proximal stomach relaxation. However, there are reports that a 5-HT 4 agonist and an adrenergic α 2 agonist have a fundus relaxation effect (Tack et al., 1998a; Tack et al., 2004) .
Visceral analgesic eff ect
In the past decade, treatment development for functional gastrointestinal diseases (FGIDs) has focused on gastrointestinal motility. Particularly for IBS, several agents were developed to correct bowel movement, but the overall effect was not suffi cient. Thus, visceral hypersensitivity was targeted as an alternative approach for FGID treatment development . Visceral hypersensitivity is the lowered perception and pain threshold to visceral stimuli that normal subjects do not perceive, and this is related to the visceral pain experienced by FGID patients (Mayer and Gebhart, 1994) . Visceral hypersensitivity was identifi ed as a major therapeutic target of many gastrointestinal disorders, including irritable bowel syndrome, functional dyspepsia, gastroesophageal refl ux disease, and gastroparesis. Currently, there is no established agent for correcting visceral hypersensitivity, but several agents are being developed. Psychotropic agents and antidepressants are often used to correct visceral hypersensitivity in FD but the true benefi t was not yet been fully proven (Tack and Janssen, 2011b) .
There is no other method to evaluate analgesia in animals except through the use of surrogate markers, for example abdominal contraction or change of blood pressure . Various stimulations inducing pain and discomfort can be used: distension of the lumen of the intestine, chemical irritant contact with the intestine, and parasitic infection. Experimentally, visceral hypersensitivity can also be induced by neonatal maternal separation and neonatal experiences of pain (Al-Chaer et al., 2000; Lidow, 2002; Lin and Al-Chaer, 2003; Chung et al., 2007a; Chung et al., 2007b) .
In gastric distention induced nociception model, DA-9701 showed an analgesic effect: the perception of intragastric distension and the perception threshold was increased dose dependently and signifi cantly in canine (unpublished). In colorectal distension induced model also, DA-9701 showed analgesic effect (unpublished). Furthermore corydaline and tetrahydropalmatine, the AI of DA-9701, was known to have antinociceptive effects on visceral and somatic nociception in rats (Wang et al., 2010; Cao et al., 2011) . The pain signal that arises from the peripheral region transfers to the spinal cord (dorsal root ganglion) and there the information is processed for transfer to the central nervous system (CNS). It is certain that DA-9701 has an effect at the pain signal transduction level and is related with downregulation of phosphorylated extracellular-signal-regulated kinase (p-ERK) (unpublished).
DA-9701 has a high affi nity to multiple receptors related to gastrointestinal function. Among them, it was suggested that 5-HT 1A and adrenergic α 2 might be involved in increased perception and pain threshold. The affi nity of DA-9701 to 5-HT 1A and adrenergic α 2 receptors are 6.87 and 4.81 μg/ml respectively. 5-HT 1A agonism was known to relax smooth muscle (Coulie et al., 1999; De Ponti et al., 2003) , a possible mechanism of increased perception (Kuiken et al., 2005) and pain threshold related to tension-sensitive mechanoreceptor inactivation (Blackshaw et al., 1987) . Moreover, an adrenergic α 2 agonist was known to have antinociceptive effect to visceral, somatic and noxious stimuli (Wang and Mo, 1989; Danzebrink and Gebhart, 1990; Harada et al., 1995) .
Prokinetic eff ect
The prokinetic effect was the traditional therapeutic target of FGIDs for the treatment of impaired gastrointestinal motility and the fundamental feature of gastrointestinal prokinetics. Prokinetics was traditionally regarded as the fi rst step of PDS (postprandial distress syndrome), with an assumption that delayed gastric emptying was a major pathophysiological mechanism and that most symptoms arise from it (Tack, 2008) . However, delayed gastric emptying did not well corre- (Kessler et al., 1991) . (1) Coulie et al., 1999; Herman et al., 2008, (2) Tack et al., 2004, (3) Nagahata et al., 1992, (4) Dumuis et al., 1989; Taniyama et al., 1991, Tack et al., 1998a. late with other symptoms suggesting other causes of the symptoms might be present (Tack et al., 1998b; Tack et al., 2001) .
There are numerous animal models to evaluate the effect of enhanced gastric emptying. In rat, the method of administering a meal and measuring the amount of remaining meal after a period of time is widely used to evaluate gastric emptying. The meals used for experimental purposes vary according to the purpose of the experiment, and include semisolid meals, solid meals, and liquid meals. A pathophysiological model of delayed gastric emptying includes delayed gastric emptying by dopamine, cisplatin, and opioids (Ramsbottom and Hunt, 1970; Tanila et al., 1993; Hirokawa et al., 1998) . Intestinal transit is also widely used for evaluating intestinal motility. A pathophysiological model includes delayed gastrointestinal transit by opioids or postoperative ileus (Galligan and Burks, 1983; Tanila et al., 1993) . Marker materials used for transit studies include charcoal and FITC-conjugated, amongst others (Miller et al., 1981; Williams et al., 1992) .
The ability for DA-9701 to promote gastric emptying and gastrointestinal transit was evaluated in these models, and showed comparable prokinetic effects with other prokinetics . DA-9701 enhances gastric emptying and gastrointestinal transit via dopamine D 2 antagonism and 5-HT 4 agonism (Lim et al., 2012) . The receptor affi nities of DA-9701 to D 2 receptor and 5-HT 4 receptor are 0.381 and 13.2 μg/ml, respectively (Eurofi ns Panlabs). There can be some argue on coexistence of relaxation effect and contraction effect on stomach but, it can be explained by one report about serotonergic receptors' distribution in stomach in which contractile receptors were dominant in antrum region and relaxing receptors were dominant in fundus region.
SAFETY OF DA-9701
The LD 50 of DA-9701 was found to be 2,000 mg/kg as a single treatment, and the no observed adverse effect level (NOAEL) was identifi ed as 150 mg/kg in a pivotal repeated treatment study (26 weeks) in rats. NOAEL was 100 mg/kg in both 1-week and 13-week repeated-treatment studies in dogs. DA-9701 had no genotoxicity. The hyperprolactinemia due to D 2 antagonism, which is one of major mechanisms of action of DA-9701, was one of the safety concerns. The prolactin ED 200 of DA-9701 was about 70-fold lower than itopride (3.78 vs 270.1 mg/kg) in rats (Fig. 2) . The CNS distribution of corydaline, one of the marker compounds of DA-9701, was studied because D 2 antagonists such as metoclopramide had a direct effect on the CNS across the blood brain barrier. The pharmacologically effective concentration of corydaline is greater than 15 μM (Adsersen et al., 2007; Ma et al., 2008) . The distribution of corydaline was not as much enough to have a pharmacological effect based on the blood concentration of 12.42~17.64 nM using the human dose. Chlorogenic acid, another marker compound of DA-9701, does not cross the blood brain barrier. 5-HT 4 agonism is involved in DA-9701 pharmacology, and 5-HT 4 agonist such as cisapride and tegaserod were withdrawn from the market due to adverse cardiac effects. Thus, a single-treatment study in beagle dog and rat was performed using telemetry to assess cardiac safety. No abnormal event was observed up to 250 mg/kg in dog and 100 mg/kg in rat. This is 67-and 167-fold higher than the human dose, respectively.
SUMMARY
FD is a highly prevalent chronic gastrointestinal disorder that is of considerable burden to both the patient and society. First of all, the pathophysiology should be understood completely for better treatment but, it may be a long way. Multiple action mechanisms may be a good solution for multifactorial and chronic disease. DA-9701 is a leading phytomedicine which implicated the possibility of multiple drug target synergism versus single molecular target against functional dyspepsia which has complex pathophysiology.
DA-9701 showed a benefi cial effect on gastric accommodation, visceral hypersensitivity, gastrointestinal motility and possibly stress-induced disorder in vivo. These effects counteract major pathophysiological causes of FD, and good clinical outcome is anticipated. Moreover, in FD there are some overlapping features with the other FGIDs and thus the effect of Motilitone may not be limited to FD. versus itopride in SD rat (In briefly, blood was recovered in 30 min after drug administration in 8 weeks old SD rats and the prolactn level was analyzed by Rat PRL Elisa kit (AER011) within 6 hours from recovery. 5 animals were used in each group. Open bar; control, dark gray bar; motilitone, Black bar; Itopride *p<0.05, **p<0.01 vs. control; student's t-test, value of result; Mean ± SD).
